

GLAXOSMITHKLINE PLC
Form 6-K
November 08, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending November 2011

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8th November 2011

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline Share Option Plan - Ordinary Shares
Period of return: From: 1 May 2011 To: 31 October 2011
Balance of unallotted securities under scheme(s) from 1,260,191
previous return:
Plus: The amount by which the block scheme(s) has been 10,000,000
increased since the date of the last return (if any increase
has been applied for):
Less: Number of securities issued/allotted under scheme(s) 6,815,650
during period (see LR3.5.7G):
Equals: Balance under scheme(s) not yet issued/allotted at 4,444,541
end of period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8th November 2011

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline Share Option Plan - ADS
Period of return: From: 1 May 2011 To: 31 October 2011
Balance of unallotted securities under scheme(s) from 2,452,512
previous return:
Plus: The amount by which the block scheme(s) has been 5,000,000
increased since the date of the last return (if any increase
has been applied for):
Less: Number of securities issued/allotted under scheme(s) 4,204,806
during period (see LR3.5.7G):

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Equals: Balance under scheme(s) not yet issued/allotted at 3,247,706
end of period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8th November 2011

Name of applicant: GlaxoSmithKline plc
Name of scheme: Glaxo Wellcome UK Share Option Scheme
Period of return: From: 1 May 2011 To: 31 October 2011
Balance of unallotted securities under scheme(s) from
previous return: 5,119,750
Plus: The amount by which the block scheme(s) has been
increased since the date of the last return (if any increase 0
has been applied for):
Less: Number of securities issued/allotted under scheme(s) 0
during period (see LR3.5.7G):
Equals: Balance under scheme(s) not yet issued/allotted at 5,119,750
end of period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8th November 2011

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	Glaxo Wellcome International Share Option Scheme		
Period of return:	From:	1 May 2011	To: 31 October 2011
Balance of unallotted securities under scheme(s) from previous return:		13,267,156	
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0	
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		0	
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		13,267,156	

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8th November 2011

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	Glaxo Wellcome 1999 Share Option Plan		
Period of return:	From:	1 May 2011	To: 31 October 2011
Balance of unallotted securities under scheme(s) from previous return:		1,040,000	
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0	
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		0	
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		1,040,000	

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8th November 2011

Name of applicant:	GlaxoSmithKline plc		
Name of scheme:	SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares		
Period of return:	From:	1 May 2011	To: 31 October 2011
Balance of unallotted securities under scheme(s) from previous return:		163,606	
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0	
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		0	
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		163,606	

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8th November 2011

Name of applicant:	GlaxoSmithKline plc
Name of scheme:	SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Period of return:	From:	1 May 2011	To:	31 October 2011
Balance of unallotted securities under scheme(s) from previous return:		275,420		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		0		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		275,420		

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8th November 2011

Name of applicant:		GlaxoSmithKline plc		
Name of scheme:		SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - Ordinary		
Period of return:	From:	1 May 2011	To:	31 October 2011
Balance of unallotted securities under scheme(s) from previous return:		100,000		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		0		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		100,000		

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 8th November 2011

Name of applicant:	GlaxoSmithKline plc
Name of scheme:	GlaxoSmithKline Savings Related Share Option Scheme
Period of return:	From: 1 May 2011 To: 31 October 2011
Balance of unallotted securities under scheme(s) from previous return:	3,090,723
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	5,000,000
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	297,307
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	7,793,416

Name of contact:	Victoria Whyte
Telephone number of contact:	020 8047 5000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: November 8, 2011

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc